Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement
- PMID: 25928337
- DOI: 10.1093/ndt/gfv050
Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement
Abstract
This paper reflects the position of the CKD-MBD workgroup, an official working group of ERA-EDTA and of the ERBP advisory board, the official guideline-producing body of ERA-EDTA, on the topic of the use of calcimimetics in patients with CKD stage 5D, as based on two recent meta-analysis.
Keywords: calcimimetics.
© The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
MeSH terms
Substances
LinkOut - more resources
Medical